Immunomodulatory Research Peptides

Immunomodulatory peptides act through specific immune-signalling pathways rather than general stimulation or suppression. This category includes thymosin alpha-1, KPV, and VIP — three molecules with very different mechanisms that converge on immune regulation.

Thymosin alpha-1 is the most clinically documented: a 28-amino-acid thymic peptide studied as a TLR2/TLR9 agonist that promotes dendritic-cell activation and T-cell maturation, with regulatory approvals in over 30 countries outside the US. At three residues, KPV is the C-terminal fragment of alpha-MSH that retains the parent hormone's anti-inflammatory signalling, best known from rodent inflammatory-bowel-disease models and its unusual PepT1-mediated intracellular uptake. VIP is a native neuropeptide with documented suppression of pro-inflammatory cytokines and promotion of regulatory T-cell responses.

All immunomodulatory peptides are independently tested for purity, endotoxin and heavy metals, with certificates published per batch. For research use only — not for human or veterinary use.